The BIO International Convention 2025 is set to commence in Boston on June 16, attracting over 20,000 professionals from more than 80 countries.

Key topics at the convention will include AI-driven drug development and biotech investment, with a focus on investment areas and growth frontiers.

Experts at the convention will discuss strategies to build talent pipelines that align research, industry, and academia, aiming to fully leverage AI in drug discovery.

Finally, the 'Return on Innovation' session will seek to redefine ROI for biotech by focusing on market adoption and the scalability of innovative technologies.

One of the highlights will be the 'AI Summit: What is Working? What is Next?', which will demonstrate how AI tools are reducing early-stage drug development timelines by 30% to 50% and enhancing drug candidate screening.

Additionally, the 'Oncology Investment Themes' session will showcase oncology as the most vibrant area in drug development, featuring nearly 200 products currently in Phase III trials and a notable shift towards novel therapies such as antibody-drug conjugates and cell therapies.

The session titled 'The State of Emerging Biotechs' will analyze the current landscape of emerging biotech firms, addressing venture capital, public market funding, and R&D pipeline strategies in light of market challenges.

Despite these advancements, the session 'We Still Need the People' will emphasize the ongoing shortage of cross-disciplinary talent in AI and drug development as a significant barrier.